
Keywords: NMSC; non-melanocytic skin cancer; BCC; basal cell carcinoma; SCC; squamous cell carcinoma; CEA; cost-effectiveness analysis; CBA; cost-benefit analysis; LYS; life-year saved; HALY; health-adjusted life-year; ROI; return on investment; NSB; net social ben